Last reviewed · How we verify
AMOR-1
AMOR-1 is a small molecule that targets the PI3K/AKT signaling pathway.
AMOR-1 is a small molecule that targets the PI3K/AKT signaling pathway. Used for Phase 2 clinical trials for metastatic triple-negative breast cancer.
At a glance
| Generic name | AMOR-1 |
|---|---|
| Sponsor | Amorphical Ltd. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K/AKT pathway, AMOR-1 aims to reduce tumor growth and proliferation. This mechanism is being explored for its potential in treating various types of cancer.
Approved indications
- Phase 2 clinical trials for metastatic triple-negative breast cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults (PHASE2)
- Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMOR-1 CI brief — competitive landscape report
- AMOR-1 updates RSS · CI watch RSS
- Amorphical Ltd. portfolio CI